Warning: session_start(): open(/opt/alt/php74/var/lib/php/session/sess_b46fa988cea115165a47e358232ee86a, O_RDWR) failed: Disk quota exceeded (122) in /home/useaicwl/public_html/wp-content/themes/mushroomstocks/functions.php on line 278

Warning: session_start(): Failed to read session data: files (path: /opt/alt/php74/var/lib/php/session) in /home/useaicwl/public_html/wp-content/themes/mushroomstocks/functions.php on line 278
DEA Chief: “Marijuana is not medicine.” - Mushroomstocks | Mushroomstocks
Albert Labs announces Strategic Investment from Cantheon Capital LLC for First In-Human TrialsMindMed Reports Full Year 2022 Financial Results and Business HighlightsCybin to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceNuminus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023Braxia Scientific Provides Update on Proposed Irwin Transaction; Company Retains Strategic Clinical Assets and Ketamine Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023Irwin Naturals Signs Letter of Intent to Acquire Braxia ScientificNuminus Wellness Inc. Reports Q1 2023 ResultsIrwin Naturals and Braxia Scientific Announce Partnership for In-Human Clinical Studies Supporting Pharmaceutical CompanNuminus Develops Mushroom Tea for Use in Psychedelic ResearchIs the Psychedelic Sector Poised for a Comeback?!?PSYC + Nucleus Form New Partnership to Develop and Launch Psychedelic FinderWhat You Need to Know About Numinus Wellness…Numinus provides update on acquisition integration and announces new client financing optionsPSYC Corp’s Psychedelic Spotlight Surpasses One Million Page Views for Fourth Consecutive MonthNuminus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022The Psychedelic Sector is Quietly Outperforming the S&P 500PSYC Completes and Publishes 2021 Audited Financials; Will Begin Audit of Q1 & Q2 2022Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022PSYC’s Bonfire Platform Development Progresses; Will Host Free Virtual Community Event on August 29th

DEA Chief: “Marijuana is not medicine.”

May 28, 2017 • 2:13 PM EDT
Aurora Germany (1).png
3 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

These senseless comments come from Chuck Rosenberg, the acting chief of the Drug Enforcement Administration (DEA) during a speech at an Ohio hospital.

Rosenberg said, “If it turns out that there is something in smoked marijuana that helps people, that’s awesome. I will be the last person to stand in the way of that. But let’s run it through the Food and Drug Administration process, and let’s stick to the science on it.”

Although Rosenberg’s tone toward medical marijuana has not changed since he became chief of the DEA in 2015, these comments are more concerning due to recent anti-cannabis rhetoric from members of the Trump administration.

Cannabis has Medical Benefits and the Time to Act is Now

Painkillers have become a serious issue in the United States. During the past 15 years, America has seen a tremendous growth in both the sales of prescription opiates and the number of people who die each year from abusing them.

Researchers from the RAND Corporation and the University of California-Irvine (UCI) may have found the answer and that is marijuana. The researchers discovered a reduction in the number of opioids related overdoses, as well as a reduction in number of admissions to addiction treatment center in states that legalized marijuana. The researchers also found that these states experienced significant reductions in both measures if they also legalized marijuana dispensaries.

In the states where doctors can prescribe marijuana, but retail dispensaries are prohibited, the study found no evidence of reductions in substance abuse or mortality. In the states where medical marijuana dispensaries are allowed, the researchers found a 16% reduction in opioid-related mortality and 28% reduction in opioid-abuse treatment admissions.

Ample Evidence Supports Medical Benefits of Cannabis

Tetrahydrocannabinol (THC) and cannabidiol (CBD) are two completely different chemical compounds. Over the last few years, researchers have found that THC helps with pain management, anxiety, and nausea, but they have barely cracked the surface since cannabis has been illegal for the last century.

Although there is less research supporting the medical benefits associated with CBD, studies have found that it reduces pain, can impact mood and anxiety, and act like an anti-inflammatory and a neuro-protectant.

The National Academies of Science, Medicine and Engineering recently conducted a study and found strong evidence for cannabis as an effective treatment for chronic pain when compared to a placebo.

Less than two years ago, the National Cancer Institute updated its website to include various studies revealing how cannabis may inhibit tumor growth by killing cells, blocking cell growth, and blocking the development of blood vessels needed by tumors to grow. The institute also said that cannabis does this while protecting healthy cells.

Before that, the National Institute on Drug Abuse revised their April 2015 publication after it found that cannabis can kill certain cancer cells and reduce the size of others.

A few months earlier, the Journal of Urology reported a study by scientists who reported that cannabis helps lower the risk of bladder cancer for males. The researchers said that cannabis usage lowers the risk of developing bladder cancer by 45%.

The Time to Act is Now

Although clinical research is very important, the current Schedule I label makes it challenging for companies to conduct research on the plant. Companies like GW Pharmaceuticals (GWPH) have proven that cannabis has medical benefits and the time to act is now.

From epilepsy to cancer, from diabetes to heart disease, cannabis can improve daily life for millions of people across the globe.  

Share Share - Facebook Share - Twitter


Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Mushroomstocks.com. Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.


Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.

Fatal error: Uncaught ErrorException: md5_file(/home/useaicwl/public_html/wp-content/litespeed/css/cfd94ce66df5f654603aae49401c95e8.css.tmp): failed to open stream: No such file or directory in /home/useaicwl/public_html/wp-content/plugins/litespeed-cache/src/optimizer.cls.php:126 Stack trace: #0 [internal function]: litespeed_exception_handler(2, 'md5_file(/home/...', '/home/useaicwl/...', 126, Array) #1 /home/useaicwl/public_html/wp-content/plugins/litespeed-cache/src/optimizer.cls.php(126): md5_file('/home/useaicwl/...') #2 /home/useaicwl/public_html/wp-content/plugins/litespeed-cache/src/optimize.cls.php(797): LiteSpeed\Optimizer->serve('https://mushroo...', 'css', true, Array) #3 /home/useaicwl/public_html/wp-content/plugins/litespeed-cache/src/optimize.cls.php(319): LiteSpeed\Optimize->_build_hash_url(Array) #4 /home/useaicwl/public_html/wp-content/plugins/litespeed-cache/src/optimize.cls.php(252): LiteSpeed\Optimize->_optimize() #5 /home/useaicwl/public_html/wp-includes/class-wp-hook.php(310): LiteSpeed\Optimize->f in /home/useaicwl/public_html/wp-content/plugins/litespeed-cache/src/optimizer.cls.php on line 126